Study on the microRNA Expression Level in Postmenopausal Osteoporosis

Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02128009

Acronym

microRNA

Enrollment

Registered

2014-05-01

Start date

2014-02-28

Completion date

2017-01-31

Last updated

2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteoporosis

Brief summary

The miRNA plays an important regulation role in gene expression, and also closely related to bone metabolism. Previous research found that postmenopausal osteoporosis with kidney Yin deficiency syndrome (POP) is associated with CLCF1 gene. This project proposed by bioinformatics prediction CLCF1 targeted regulation of miRNAs, and use the 3 'UTR dual luciferase report system for target validation, aimed at the miRNA levels to explore postmenopausal osteoporosis molecular mechanism with kidney Yin deficiency syndrome.

Interventions

OTHERosteoporosis

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

45 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent. * Female ages 45 to 75 had gone through natural menopause before two years * In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate; * In accordance with the western medicine diagnostic criteria; * In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study.

Exclusion criteria

* Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods * Age: \<44 and \> 76 years old; * With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor; * With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases; * Psychosis or alzheimer's patients; * Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.; * This medicine allergic constitution or composition of known to have allergies; * In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;

Design outcomes

Primary

Measure	Time frame
microRNA expression lever in the Peripheral Blood	one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026